HIGHLIGHTS
- What: The authors examined the properties of the OPC5-related V2R agonists on six partial cNDI-causing V2R mutants (V882.53M, Y1283.41S, L1614.47P, T2736.37M, S3298.47R and S3338.51del (superscripts denote Ballesteros-Weinstein residue numbers )). The authors focused on the nonpeptidic V2R agonist OPC-51803 (OPC5) and its nine analogues (OPC16b, OPC16g, OPC16j, OPC19a, OPC19b, OPC23b, OPC23d, OPC23h and OPC23i) (Fig 1A and S1 Table). This study investigated the pharmacological activity of non-peptidic V2R agonists against partial cNDI-associated V2R mutants.
- Who: Ritsuki Kuramoto and collaborators from the Graduate School of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.